The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.

ABSTRACT:

Background

With a 15% incidence, KRAS is one of the most common mutations in biliary tract cancer (BTC) and is a poor prognostic factor. Immune checkpoint inhibitors (ICIs) as salvage therapy have modest activity in BTC.

Objectives

There are limited data on the efficacy of ICIs according to KRAS mutation in BTC. We evaluated the efficacy of ICIs in BTC patients with or without KRAS mutations.

Design

Retrospective observational study.

Methods

We conducted molecular profiling in BTC patients who received ICIs as salvage therapy. The expression of programmed death ligand 1 (PD-L1) on tumor cells was assessed using immunohistochemistry. The TruSight^TM Oncology 500 assay from Illumina was used as a cancer panel. We analyzed overall survival (OS) and progr

SUBMITTER: Jeong SY 

PROVIDER: S-EPMC10164250 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature